A detailed history of Vanguard Group Inc transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,727,248 shares of ALXO stock, worth $3.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,727,248
Previous 1,566,464 10.26%
Holding current value
$3.23 Million
Previous $17.5 Million 40.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.84 - $17.56 $938,978 - $2.82 Million
160,784 Added 10.26%
1,727,248 $10.4 Million
Q1 2024

May 10, 2024

BUY
$10.95 - $16.79 $701,402 - $1.08 Million
64,055 Added 4.26%
1,566,464 $17.5 Million
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $2.38 Million - $7.6 Million
494,173 Added 49.01%
1,502,409 $22.4 Million
Q3 2023

Nov 14, 2023

BUY
$4.19 - $7.35 $6,905 - $12,112
1,648 Added 0.16%
1,008,236 $4.84 Million
Q2 2023

Aug 14, 2023

SELL
$4.37 - $9.56 $126,515 - $276,771
-28,951 Reduced 2.8%
1,006,588 $7.56 Million
Q1 2023

May 15, 2023

SELL
$4.52 - $11.71 $1.76 Million - $4.56 Million
-389,759 Reduced 27.35%
1,035,539 $4.68 Million
Q4 2022

Feb 10, 2023

BUY
$9.51 - $12.95 $135,888 - $185,042
14,289 Added 1.01%
1,425,298 $16.1 Million
Q3 2022

Nov 14, 2022

BUY
$8.23 - $15.14 $710,018 - $1.31 Million
86,272 Added 6.51%
1,411,009 $13.5 Million
Q2 2022

Aug 12, 2022

SELL
$5.89 - $19.46 $2.07 Million - $6.83 Million
-350,919 Reduced 20.94%
1,324,737 $10.7 Million
Q1 2022

May 13, 2022

SELL
$13.65 - $22.06 $441,959 - $714,258
-32,378 Reduced 1.9%
1,675,656 $28.3 Million
Q4 2021

Feb 14, 2022

BUY
$21.49 - $74.4 $612,593 - $2.12 Million
28,506 Added 1.7%
1,708,034 $36.7 Million
Q3 2021

Nov 12, 2021

BUY
$52.51 - $80.91 $6.82 Million - $10.5 Million
129,810 Added 8.38%
1,679,528 $124 Million
Q2 2021

Aug 13, 2021

BUY
$52.2 - $75.23 $80.9 Million - $117 Million
1,549,718 New
1,549,718 $84.7 Million

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $76.2M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.